
|Articles|May 24, 2022
Daily Medication Pearl: Prezista (Darunavir)
Author(s)Saro Arakelians, PharmD
Prezista is an protease inhibitor indicated for the treatment of HIV-1 infection in patients aged 3 years and older.
Advertisement
Medication Pearl of the Day: Prezista (Darunavir)
Indication: Prezista is an protease inhibitor indicated for the treatment of HIV-1 infection in patients aged 3 years and older.
Insights:
- Dosing: Treatment-experienced and -naïve adult patients with no darunavir resistance-associated substitutions: 800 mg (2 400-mg tablets) taken with ritonavir 100 mg once daily and with food
- Dosage forms: 100 mg/mL oral suspension-75 mg tablets, 150-mg tablets, 400-mg tablets, and 600-mg tablets
- Adverse events: The most common clinical adverse drug reactions to Prezista/ritonavir (an incidence equal to greater than 5%) of at least moderate intensity (equal to or greater than grade 2) were abdominal pain, headaches, diarrhea, nausea, rash, and vomiting.
- Mechanism of action: Darunavir is an HIV-1 antiviral drug.
- Manufacturer: Janssen Pharmaceuticals
Source:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Breaking News: AstraZeneca, White House Announce Most-Favored-Nation Deal
2
New Report Details Rising Incidence of Invasive Lobular Carcinoma
3
Tramadol and Antidepressants Linked to Increased Seizure Risk in Older Adults
4
FDA Approves Expanded Indication for Risperidone Extended-Release Injectable to Treat Bipolar I Disorder
5